What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

December 8, 2025BloodOpen Access

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals poorer outcomes for older AML patients with RAS mutations and NPM1 mutations, suggesting need for new therapies.

Overall survival was significantly affected by the presence of RAS mutations in older acute myeloid leukemia patients.
A total of 187 patients with favorable- or intermediate-risk AML were analyzed, median overall survival was 48.6 weeks.
Mutation analysis used next-generation sequencing to assess genetic factors influencing outcomes in acute myeloid leukemia.
Findings stress the importance of new treatment strategies targeting RAS mutations combined with venetoclax and azacitidine.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals poorer outcomes for older AML patients with RAS mutations and NPM1 mutations, suggesting need for new therapies.

Overall survival was significantly affected by the presence of RAS mutations in older acute myeloid leukemia patients.
A total of 187 patients with favorable- or intermediate-risk AML were analyzed, median overall survival was 48.6 weeks.
Mutation analysis used next-generation sequencing to assess genetic factors influencing outcomes in acute myeloid leukemia.
Findings stress the importance of new treatment strategies targeting RAS mutations combined with venetoclax and azacitidine.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark